[go: up one dir, main page]

HUP0104702A3 - Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises - Google Patents

Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises

Info

Publication number
HUP0104702A3
HUP0104702A3 HU01047020104702A HUP0104702A HUP0104702A3 HU P0104702 A3 HUP0104702 A3 HU P0104702A3 HU 01047020104702 A HU01047020104702 A HU 01047020104702A HU P0104702 A HUP0104702 A HU P0104702A HU P0104702 A3 HUP0104702 A3 HU P0104702A3
Authority
HU
Hungary
Prior art keywords
suppression
snoring
agent
ntherapeutic
oises
Prior art date
Application number
HU01047020104702A
Other languages
English (en)
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Publication of HUP0104702A2 publication Critical patent/HUP0104702A2/hu
Publication of HUP0104702A3 publication Critical patent/HUP0104702A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU01047020104702A 1998-12-10 1999-12-10 Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises HUP0104702A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (de) 1998-12-10 1998-12-10 Therapeutikum zur Unterdrückung von Schnarchgeräuschen
PCT/EP1999/009791 WO2000033863A2 (de) 1998-12-10 1999-12-10 Therapeutikum zur unterdrückung von schnarchgeräuschen

Publications (2)

Publication Number Publication Date
HUP0104702A2 HUP0104702A2 (hu) 2002-04-29
HUP0104702A3 true HUP0104702A3 (en) 2003-09-29

Family

ID=7890562

Family Applications (1)

Application Number Title Priority Date Filing Date
HU01047020104702A HUP0104702A3 (en) 1998-12-10 1999-12-10 Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises

Country Status (21)

Country Link
US (1) US6573241B1 (hu)
EP (1) EP1137430B1 (hu)
JP (1) JP4700811B2 (hu)
KR (1) KR100859556B1 (hu)
CN (1) CN1186095C (hu)
AT (1) ATE234108T1 (hu)
AU (1) AU764744B2 (hu)
BR (1) BR9915800A (hu)
CA (1) CA2353469A1 (hu)
CZ (1) CZ295769B6 (hu)
DE (2) DE19856897A1 (hu)
DK (1) DK1137430T3 (hu)
ES (1) ES2192880T3 (hu)
HK (1) HK1040636B (hu)
HU (1) HUP0104702A3 (hu)
IL (2) IL143528A0 (hu)
NO (1) NO328762B1 (hu)
PL (1) PL202908B1 (hu)
PT (1) PT1137430E (hu)
RU (1) RU2243783C2 (hu)
WO (1) WO2000033863A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CA2611936C (en) * 2005-06-14 2017-01-03 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
AU2006346369B2 (en) * 2005-07-18 2013-02-21 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2008006750A (es) 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
AU2007329579A1 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
WO2008140594A2 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
US20120225094A1 (en) * 2009-11-09 2012-09-06 Ira Sanders Treatment of Sleep Disordered Breathing with Neurotoxin
PL2677029T3 (pl) 2011-05-19 2017-10-31 Ipsen Bioinnovation Ltd Sposoby wytwarzania poddanych obróbce proteolitycznej polipeptydów
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) * 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
RU2014016C1 (ru) * 1992-10-12 1994-06-15 Сергей Данилович Дорохов Способ лечения храпа
US5365945A (en) * 1993-04-13 1994-11-22 Halstrom Leonard W Adjustable dental applicance for treatment of snoring and obstructive sleep apnea
ES2194025T3 (es) 1993-06-10 2003-11-16 Allergan Inc Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
US5570704A (en) * 1993-10-28 1996-11-05 Snoreless Corp Universal, user-adjustable oral cavity appliance to control snoring and reduce episodes of obstructive sleep apnea
DE69427869T2 (de) * 1993-12-28 2002-04-11 Allergan Sales Inc Botulinumtoxine zur behandlung von hyperhydrosis
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
RU2095079C1 (ru) * 1995-02-27 1997-11-10 Тамара Мироновна Авилова Средство от храпа
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9316973B2 (en) 2013-06-13 2016-04-19 Lexmark International, Inc. Heat transfer system for a fuser assembly

Also Published As

Publication number Publication date
AU3037400A (en) 2000-06-26
DE19856897A1 (de) 2000-06-15
PL349334A1 (en) 2002-07-15
CZ295769B6 (cs) 2005-11-16
PL202908B1 (pl) 2009-08-31
HUP0104702A2 (hu) 2002-04-29
DK1137430T3 (da) 2003-06-16
NO20012716L (no) 2001-06-01
KR100859556B1 (ko) 2008-09-22
HK1040636B (zh) 2003-05-30
PT1137430E (pt) 2003-07-31
RU2243783C2 (ru) 2005-01-10
ATE234108T1 (de) 2003-03-15
BR9915800A (pt) 2001-09-25
WO2000033863A3 (de) 2000-11-02
WO2000033863A2 (de) 2000-06-15
EP1137430A2 (de) 2001-10-04
CN1186095C (zh) 2005-01-26
EP1137430B1 (de) 2003-03-12
AU764744B2 (en) 2003-08-28
IL143528A (en) 2008-04-13
ES2192880T3 (es) 2003-10-16
IL143528A0 (en) 2002-04-21
JP2002531516A (ja) 2002-09-24
HK1040636A1 (en) 2002-06-21
NO328762B1 (no) 2010-05-10
KR20010089527A (ko) 2001-10-06
CZ20012058A3 (cs) 2001-09-12
NO20012716D0 (no) 2001-06-01
CA2353469A1 (en) 2000-06-15
DE59904569D1 (de) 2003-04-17
US6573241B1 (en) 2003-06-03
JP4700811B2 (ja) 2011-06-15
CN1329501A (zh) 2002-01-02

Similar Documents

Publication Publication Date Title
HUP0104702A3 (en) Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises
HUP0104676A3 (en) Compositions for the treatment of anorectal disorders and their use
GB0015235D0 (en) Compositions for the treatment of skin and anorectal conditions
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
PT1073416E (pt) Utilização de óxido nítrico inalado como agente anti-inflamatório
IL136960A0 (en) Combination therapy for the treatment of migraine
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
IL133760A0 (en) Composition for the treatment of dandruff
IL148640A0 (en) Processes for the preparation of sumatriptan and related compounds
HUP0104698A3 (en) Use of riluzole for treating acoustic traumas
HUP0001891A3 (en) Medicament for the treatment of migraine
IL135994A0 (en) Combination therapy for the treatment of aids
IL136962A0 (en) Combination therapy for the treatment of migraine
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
AU1940800A (en) Combination therapy for the treatment of sepsis
IL136024A0 (en) Combination therapy for the treatment of migraine
GB9904252D0 (en) Composition for the treatment of pain
GB9805686D0 (en) Treatment of metals
GB9704174D0 (en) Agent for medical treatment
GB9922462D0 (en) The use of triazolo-pyridazine derivatives for treating hearing loss
AU1230300A (en) Intra-oral appliance for the prevention of snoring
GB9819590D0 (en) Combination therapy for the treatment of aids
GB9807938D0 (en) Combination therapy for the treatment of AIDS

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERZ PHARMA GMBH & CO. KGAA, DE

Free format text: FORMER OWNER(S): BIOTECON GESELLSCHAFT FUER BIOTECHNOLOGISCHE ENTWICKLUNG UND CONSULTING MBH, DE

FD9A Lapse of provisional protection due to non-payment of fees